̽��ֱ��

A team of researchers at the ̽��ֱ�� of Cambridge has identified a protein complex that might explain why some cancer patients treated with the revolutionary new anti-cancer drugs known as PARP inhibitors develop resistance to their medication.

̽��ֱ��past few years has seen an explosion in the number of studies using organoids – so-called ‘mini organs’. While they can help scientists understand human biology and disease, some in the field have questioned their usefulness. But as the field matures, we could see their increasing use in personalised and regenerative medicine.

̽��ֱ��Cancer Research UK Cambridge Centre has become the first UK institute to be designated a Comprehensive Cancer Center of Excellence by the European Academy of Cancer Sciences (EACS).

Scientists have created mini biological models of human primary liver cancers, known as organoids, in the lab for the first time. In a paper published in Nature Medicine, the tiny laboratory models of tumours were used to identify a new drug that could potentially treat certain types of liver cancer.